Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.38 +0.02 (+0.15%)
Official Closing Price Updated: 7:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,702,405
Open 13.37
Bid (Size) 13.39 (1)
Ask (Size) 13.65 (1)
Prev. Close 13.36
Today's Range 13.30 - 13.41
52wk Range 13.11 - 17.11
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... 
Via Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily

Performance

YTD
-6.69%
-6.69%
1 Month
-5.44%
-5.44%
3 Month
-9.53%
-9.53%
6 Month
-7.85%
-7.85%
1 Year
-20.64%
-20.64%

More News

Read More
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
From Takeda Pharmaceutical Company Limited
Via Business Wire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
Via Benzinga
Exposures Product Safety
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study
Via Benzinga
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
Via Benzinga
Takeda Announces Chief Financial Officer Succession
From Takeda Pharmaceutical Company Limited
Via Business Wire
Earnings Scheduled For February 1, 2024
Via Benzinga
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
3 Stocks to Buy to Benefit From the Booming Sleep Industry
Via InvestorPlace
Takeda Named Global Top Employer for Seventh Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
Time to buy these 3 healthcare companies that raised revenue guidance?
Via MarketBeat
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.